Table 2.
Summary of patients’ characteristics and γδ T-cell clinical outcomes (quantitative)
| aGVHD | Relapse | Viral infections | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | N | Male, n (%) | Donor age, median (range), y | Patient age, median (range), y | Donors (%) | Source | Diagnosis (n) | Conditioning (%) | GVHD prophylaxis (%) | Follow-up, median (range) | Timepoint | γδ Phenotype | Subgroups | Grade, d | n (%) | n (%) | Virus | n (%) |
| Lamb et al (1996)54 | 43 | NR | NR | NR | TCD PMRD | BM | ALL + AML (34), CML (9) | MAC (100) | CsA, MPD, ATG | 2.5 y | D+100 | Total γδ T cells | γδ T-cells percentage >10% | 1-4, <100 d | 1 (10) | 1 (10) | NR | NR |
| γδ T-cell percentage <10% | 1-4, <100 d | 12 (36) | 17 (51) | NR | NR | |||||||||||||
| Lamb et al (1999)5 | 100 | 64 (64) | 30 (1-67) | 25 (0-54) | TCD PMRD | BM | ALL + AML (58), CLL + CML (28), other (14) | MAC (100) | CsA, MPD, ATG | 35 mo | D+100 | Total γδ T cells | γδ T-cell percentage >10% | NR | NR | 1 (14) | NR | NR |
| γδ T-cell percentage <10% | NR | NR | 53 (57) | NR | NR | |||||||||||||
| Godder et al (2007)4 | 153 | 95 (62) | 27 (4-67) | 22 (0-59) | TCD PMRD | BM | AML (76), ALL (77) | MAC (100) | CsA, CST, ATG | 1771 d | 140 d | Total γδ T cells | γδ T-cell count > 1.75 × 105 cells/mL | 1-4, <3 mo | 3 (16) | 5 (27) | CMV | 1 (5) |
| γδ T-cell count <1.75 × 105 cells/mL | 1-4, <3 mo | 25 (18) | 48 (35) | CMV | 18 (13) | |||||||||||||
| Perko et al (2015)55 | 102 | 58 (57) | 11.3 (1.6-25.2) | 10.5 (0.6-25.2) | MUD (41), MRD (23), TCD haplo (31), CB (5) | BM + PB + CB | ALL (60), AML (42) | RIC (100) | CsA, MMF, MTX, FK, OKT3, CAMPATH | 2.7 y (0.12-6) | First year | Total γδ T cells | γδ T-cell count >1.5 × 105 cells/mL | 1-4, <3 mo | 3 (27) | 1 (9) | CMV | 2 (18) |
| γδ T-cell count <1.5 × 105 cells/mL | 1-4, <3 mo | 37 (40) | 19 (21) | CMV | 24 (26) | |||||||||||||
| Ho et al (2017)7 | 101 | 46 (46) | Autologous | 60 (28-75) | Autologous | PB | MM (101) | MAC (100) | Autologous | 1500 d | D+100 | Total γδ T cells | γδ T-cell count >top 3 quartiles (25$%-100) | NR | NR | 27 (35) | NR | NR |
| γδ T-cell count <lower quartile (0%-24) | NR | NR | 13 (55) | NR | NR | |||||||||||||
| Park et al (2018)56 | 50 | 25 (50) | NR | 12.1 (0.67-22.5) | TCD haplo | PB | ALL (10), AML (12), MPAL (2), JMML (2), MDS-RCC (5), lymphoma (3), SAA (8), relapsed solid tumor (5), Wiskott-Aldrich symptom (1), Kostmann syndrome (1), hemoglobinopathy (1) | MAC (100) | MMF, calcineurin inhibitors | 27 mo (13-53) | 30 d | Total γδ T cells | γδ T-cell percentage >70% | NR | NR | 1 (25) | CMV | 2 (22) |
| γδ T-cell percentage <21% | NR | NR | 5 (100) | CMV | 7 (87) | |||||||||||||
| Liu et al (2018)8 | 132 | 80 (60) | NR | 33 (18-59) | PMRD | BM + PB | ALL (50), AML (58), MDS (17), other (7) | MAC (100) | CsA, MTX, MMF | 3 mo | 30 d | Vδ2+ | Vδ2 counts >median | NR | NR | NR | EBV | 5 (7) |
| Vδ2 counts <median | NR | NR | NR | EBV | 11 (16) | |||||||||||||
| Bian et al (2018)6 | 40 | 24 (60) | 42 (14-58) | 25 (11-55) | PMRD | BM (20) + PB (20) | AML (15), ALL (21), MDS (3), other (1) | MAC (100) | CsA, MMF, MTX | 180 d | 1 mo | Total γδ, Vγ9+, Vδ1+, Vδ2+ | Vδ1 percentage >median | 2-4, <3 mo | 5 (25) | NR | CMV | 12 (60) |
| Vδ1 percentage <median | 2-4, <3 mo | 6 (30) | NR | CMV | 18 (90) | |||||||||||||
| Pabst et al (2007)17 | 63 | 41 (65) | NR | 48 (18-66) | MUD (100) | PB | AML/MDS (38), ALL (16), lymphoma (9) | MAC (100) | CsA + MTX (100) | 30.1 (0.6-62) mo | Graft | Total γδ T cells | γδ T-cels count >median | 2-4, <3 mo | 21 (66) | NR | NR | NR |
| γδ T-cell count <median | 2-4, <3 mo | 12 (40) | NR | NR | NR | |||||||||||||
| Xuan et al (2018)57 | 30 | 12 (40) | 33 (12-56) | 31 (14-47) | SIB | PB | Acute leukemia (30) | MAC (100) | CsA + MTX | 869 (147-981) d | Graft | CD27+Vδ1Tregs | CD27+Vδ1Tregs percentage >0.33% | 1-2, 100 d | 5 (22) | NR | NR | NR |
| CD27+Vδ1Tregs percentage <0.33% | 1-2, 100 d | 6 (75) | NR | NR | NR | |||||||||||||
| Gaballa et al (2019)53 | 105 | 62 (59) | 30 (23-38.5) | 52 (31.5-61) | SIB (26.7), MUD (62.8), others (10.5) | BM (16), PB (89) | Acute leukemia (54), chronic leukemia (7), MDS (19) lymphoma (6), MM (7), myelofibrosis (3), nonmalignant (9) | MAC (24.8), RIC (75.2) | CsA + MTX (92), PTCy (9), others (4) | 22 (15-30.5) mo | Graft | Total γδ, Vγ9, Vδ1, Vδ2 | Percentage total γδ >median | 1-3, 100 d | 20 (38) | 35 (67) | CMV | 33 (63) |
| Percentage total γδ <median | 1-3, 100 d | 18 (34) | 36 (68) | CMV | 32 (60) | |||||||||||||
CMV, cytomegalovirus; SAA, severe aplastic anemia.